Abstract
BackgroundWe investigated the clinical significance of serum bone-specific alkaline phosphatase (BAP), tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) and type I collagen carboxyterminal telopeptide (ICTP) as bone metabolic markers for bone metastasis (BM) screening in lung cancer patients. MethodsNewly diagnosed advanced lung cancer patients with (N=130) and without (N=135) BM were enrolled in the study. Serum BAP, TRACP 5b and ICTP were measured before the treatment. ResultsBAP, TRACP 5b and ICTP values were higher in patients with BM compared with patients without BM (all P<0.0001). Area under ROC curve (AUC) of BAP, TRACP 5b and ICTP was 0.760, 0.753 and 0.835 (all P<0.0001), respectively. The cut-off values for BAP, TRACP 5b and ICTP were 21.8μg/l, 7.8 U/l and 8.8μg/l, respectively. When TRACP 5b and ICTP were combined, AUC was elevated to 0.895 (P<0.0001), and the cut-off values were TRACP 5b 7.6 U/l and ICTP 8.4μg/l. ConclusionsWe conclude that serum BAP, TRACP 5b and ICTP may serve as useful tools for BM screening in lung cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
